The team investigated the safety of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease (IBD).
They reported their findings in the April issue of the American Journal of Gastroenterology.
A total of 27 patients with Crohn's disease, ulcerative colitis, or pouchitis, who used celecoxib or rofecoxib, were identified from computerized prescription records.
In the retrospective chart review, concomitant medications, past NSAID use, indication for cyclooxygenase-2 inhibitor, dose, and duration were obtained.
IBD disease activity before cyclooxygenase-2 inhibitor use was graded using a modified disease activity index. Change in disease activity was graded as "improved", "no change", or "worsened".
Of the patients, 11 were treated with celecoxib (median dose = 200 mg/day), and 16 were treated with rofecoxib (median dose = 25 mg/day).
| IBD symptoms exacerbated in 7% of those who took cyclooxygenase-2 inhibitors.
| American Journal of Gastroenterology |
Median duration of therapy was 9 months.
The drug was found to be beneficial in 14 patients, of partial benefit in 8, and of no benefit in 5.
The investigators found that 2 of the patients (7%) who received cyclooxygenase-2 inhibitors experienced exacerbation of IBD.
Three patients (11%) had other adverse events (renal insufficiency, rash, and asymptomatic colonic ulceration). However, all of these adverse events were reversible.
Dr Uma Mahadevan, of the University of California, San Francisco, concluded on behalf of fellow authors, "Our preliminary results suggest that cyclooxygenase-2 inhibitors may be safe and beneficial in most patients with IBD.
"A placebo-controlled trial to confirm these preliminary observations is needed."